BHC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Based on the data provided, Bausch Health Companies Inc (BHC) is not a strong buy for a beginner, long-term investor at this time. The stock shows bearish technical indicators, weak financial performance, and lacks significant positive catalysts. It is better to hold off on investing in this stock until more favorable conditions arise.
The MACD is slightly positive at 0.0163 and expanding, but RSI is neutral at 47.718, indicating no clear momentum. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading near its pivot point of 5.093. Support levels are at 4.955 and 4.871, while resistance levels are at 5.231 and 5.315. Overall, the technical indicators suggest a bearish trend.
The company's gross margin increased to 63.02%, up 2.52% YoY, indicating some operational efficiency improvement.
Analysts have lowered price targets (Barclays to $7, Truist to $
and maintain neutral or hold ratings.
The Phase 3 RED-C program failed to meet its primary endpoint, limiting future growth opportunities.
Loss of exclusivity for key products like Xifaxan by 2027 is a significant concern.
Stock trend analysis predicts a potential decline of -3.71% in the next week and -4.41% in the next month.
In Q4 2025, revenue increased by 9.26% YoY to $2.796 billion, but net income dropped significantly to -$112 million (-220.43% YoY), and EPS fell to -0.3 (-220% YoY). While gross margin improved to 63.02%, the overall financial performance indicates declining profitability.
Analysts maintain neutral or hold ratings with price targets between $7 and $8. Concerns include loss of exclusivity for key drugs and limited growth opportunities in the pipeline.
